• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The potential of trastuzumab deruxtecan as a tissue agnostic drug
Oncology. 2023 Aug 31. doi: 10.1159/000533866. Online ahead of print.ABSTRACTBACKGROUND: Many modern anticancer drugs are designed to target specific molecular alterations harbored by the cancer. If a specific drug is able to target these alterations, regardless of the organ or tissue in which the cancer originates, it will often be characterized as a tissue- or tumor agnostic drug. According to the Food and Drug Administration (FDA), a tissue agnostic drug refers to a drug that targets a specific molecular alteration across multiple cancer types, as defined by organ, tissue, or tumor type.SUMMARY: Over the last six years,...
Source: Oncology - August 31, 2023 Category: Cancer & Oncology Authors: Jan Tr øst Jørgensen Source Type: research

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
CONCLUSIONS: We provide rationale for combining T-DXd with adavosertib in HER2-expressing cancers, especially with co-occuring CCNE1 amplifications.PMID:37279095 | DOI:10.1158/1078-0432.CCR-23-0103
Source: Clinical Cancer Research - June 6, 2023 Category: Cancer & Oncology Authors: Timothy P DiPeri Kurt W Evans Maria Gabriela Raso Ming Zhao Yasmeen Q Rizvi Xiaofeng Zheng Bailiang Wang Bryce P Kirby Kathleen Kong Michael Kahle Timothy A Yap Ecaterina E Ileana Dumbrava Jaffer A Ajani Siqing Fu Khandan Keyomarsi Funda Meric-Bernstam Source Type: research

A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung
Cureus. 2023 Apr 28;15(4):e38271. doi: 10.7759/cureus.38271. eCollection 2023 Apr.ABSTRACTLung cancer is the foremost reason for cancer-related mortality among men and women. The ultimate goal of patient supervision post-diagnosis for advanced cases is to improve survival and quality of life with minimal treatment-associated side effects. With advancements in genomic medicine and a better understanding of cell signaling pathways, many actionable gene mutations have been identified in lung carcinoma, which drastically improve survival outcomes. Mutations in human epidermal growth factor receptor 2 (HER2) and epidermal growt...
Source: Cancer Control - May 31, 2023 Category: Cancer & Oncology Authors: Arun Warrier Anu George Vipulkumar Thummar Priya Mehta Source Type: research

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
CONCLUSIONS: Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy. ctDNA testing for ERBB2 status prior to treatment will spare patients from repeat tissue biopsies, which may be reserved for reflex testing when ctDNA is not detected.PMID:37104758 | DOI:10.46883/2023.25920992
Source: Oncology (Williston Park, N.Y.) - April 27, 2023 Category: Cancer & Oncology Authors: Daniel Vt Catenacci Yoon-Koo Kang Hope E Uronis Keun-Wook Lee Matthew Ch Ng Peter C Enzinger Se Hoon Park Philip J Gold Jill Lacy Howard S Hochster Sang Cheul Oh Yeul Hong Kim Kristen A Marrone Ronan J Kelly Rosalyn A Juergens Jong Gwang Kim Thierry Alcin Source Type: research

Pages: 1  2  3  4  5  6  7  8